TCG Crossover's 9.99% Agenus Stake Consists Mostly Of Warrants

The fund holds 603,892 common shares, with exercisable warrants accounting for most of its reported position.

Share
TCG Crossover's 9.99% Agenus Stake Consists Mostly Of Warrants

TCG Crossover Fund III reported a 9.99% beneficial stake in Agenus, which develops immunotherapies for cancer and infectious disease, in a passive ownership disclosure filed Monday. The 4,954,779-share position consists mostly of shares the fund can obtain through warrants.

Warrants Account For Most Shares

The fund holds 603,892 common shares outright. Its reported position also counts 3,387,533 shares available through pre-funded warrants and 963,354 through Series B warrants, all exercisable within 60 days of the statement. Warrants give their holders the right to obtain shares.

The percentage uses a 49,597,397-share denominator: Agenus's 45,246,510 outstanding shares as of November 3, plus 4,350,887 shares available through the fund's eligible warrants.

Another 4,006,824 Series B warrant shares are excluded because exercising them would exceed a 9.99% beneficial-ownership limit. The calculation also leaves out warrants for 3,109,452 common shares under Series A warrants that cannot be exercised within the statement's 60-day window.

One Holding, Shared Authority

TCG Crossover Fund III, a Delaware limited partnership, holds the securities. Its general partner, TCG Crossover GP III, may exercise voting and investment authority over them. Chen Yu, the general partner's sole managing member, may share that authority.

The joint disclosure attributes the same holding to the fund, its general partner and Yu. They certified that the securities were acquired and are held without a purpose of changing or influencing Agenus's control. The statement identifies September 30 as the ownership event date.

Agenus's Cancer-Drug Bet

Agenus's main focus is cancer immunotherapy, led by the antibody drugs botensilimab and balstilimab. It is testing the pair in colorectal cancer and other tumors, including a global late-stage trial with the Canadian Cancer Trials Group.

Neither drug is approved for sale. Patients receive them through trials and access programs, including a program reimbursed by France's national health system. About 1,200 patients have received botensilimab and/or balstilimab in early-stage trials.

Agenus also owned about 46% of MiNK Therapeutics as of December 31, 2025, and majority-owns SaponiQx, which develops ingredients that strengthen vaccines' effects. Agenus's market value was $305 million as of 6:41 p.m. ET Monday.

Sources

More on Agenus

All Agenus (AGEN) coverage →